MX2023010430A - Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d). - Google Patents

Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).

Info

Publication number
MX2023010430A
MX2023010430A MX2023010430A MX2023010430A MX2023010430A MX 2023010430 A MX2023010430 A MX 2023010430A MX 2023010430 A MX2023010430 A MX 2023010430A MX 2023010430 A MX2023010430 A MX 2023010430A MX 2023010430 A MX2023010430 A MX 2023010430A
Authority
MX
Mexico
Prior art keywords
kras
inhibitors
compounds
methods
present disclosure
Prior art date
Application number
MX2023010430A
Other languages
English (en)
Inventor
Khehyong Ngu
Upender Velaparthi
Hasibur Rahaman
Brian Edward Fink
Robert Joseph Cherney
Wayne David Vaccaro
Zheming Ruan
Lan-Ying Qin
Pravin S Shirude
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of MX2023010430A publication Critical patent/MX2023010430A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La presente invención se refiere a inhibidores de KRAS. También se proporcionan métodos para tratar cánceres usando los compuestos.
MX2023010430A 2021-03-12 2022-03-14 Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d). MX2023010430A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163160431P 2021-03-12 2021-03-12
US202163173021P 2021-04-09 2021-04-09
US202163220386P 2021-07-09 2021-07-09
US202163236497P 2021-08-24 2021-08-24
PCT/US2022/020239 WO2022192794A1 (en) 2021-03-12 2022-03-14 Kras g12d inhibitors

Publications (1)

Publication Number Publication Date
MX2023010430A true MX2023010430A (es) 2023-09-12

Family

ID=81213567

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023010430A MX2023010430A (es) 2021-03-12 2022-03-14 Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).

Country Status (10)

Country Link
US (1) US20240317769A1 (es)
EP (1) EP4305038A1 (es)
JP (1) JP2024510606A (es)
KR (1) KR20230169967A (es)
AU (1) AU2022232523A1 (es)
BR (1) BR112023017763A2 (es)
CA (1) CA3210053A1 (es)
IL (1) IL305568A (es)
MX (1) MX2023010430A (es)
WO (1) WO2022192794A1 (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115181106B (zh) * 2021-04-07 2024-04-05 药雅科技(上海)有限公司 喹唑啉类krasg12d突变蛋白抑制剂的制备及其应用
WO2023114733A1 (en) * 2021-12-13 2023-06-22 Quanta Therapeutics, Inc. Kras modulators and uses thereof
CN118556063A (zh) * 2022-01-21 2024-08-27 上海湃隆生物科技有限公司 杂环类化合物、药物组合物及其应用
WO2023138662A1 (zh) * 2022-01-21 2023-07-27 南京明德新药研发有限公司 苯并嘧啶类化合物及其应用
AU2023218370A1 (en) 2022-02-09 2024-09-19 Quanta Therapeutics, Inc. Kras modulators and uses thereof
WO2023172940A1 (en) 2022-03-08 2023-09-14 Revolution Medicines, Inc. Methods for treating immune refractory lung cancer
CN118344386A (zh) * 2023-01-13 2024-07-16 苏州泽璟生物制药股份有限公司 取代桥环类抑制剂及其制备方法和应用
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
TW202416976A (zh) * 2022-09-16 2024-05-01 大陸商南京明德新藥研發有限公司 含六氫螺環［環丙烷—１，２＇—吡咯𠯤］的化合物
WO2024061365A1 (zh) * 2022-09-22 2024-03-28 成都奥睿药业有限公司 嘧啶并环类化合物及其制备方法与用途
CN117800975A (zh) * 2022-09-30 2024-04-02 泰励生物科技（上海）有限公司 具有抗kras突变肿瘤活性的化合物
CN117263959A (zh) * 2022-10-24 2023-12-22 药雅科技(上海)有限公司 芳香类kras突变蛋白抑制剂的制备及其应用
WO2024092420A1 (zh) * 2022-10-31 2024-05-10 上海皓元医药股份有限公司 一种((2R,7aS)-2-氟六氢-1H-吡咯嗪-7a-基)甲醇的制备方法
WO2024186680A1 (en) * 2023-03-03 2024-09-12 Frontier Medicines Corporation Methods for preparing pyrrolizidine compounds
WO2024206858A1 (en) 2023-03-30 2024-10-03 Revolution Medicines, Inc. Compositions for inducing ras gtp hydrolysis and uses thereof
WO2024211712A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors
WO2024211663A1 (en) 2023-04-07 2024-10-10 Revolution Medicines, Inc. Condensed macrocyclic compounds as ras inhibitors

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4475196A (en) 1981-03-06 1984-10-02 Zor Clair G Instrument for locating faults in aircraft passenger reading light and attendant call control system
US4447233A (en) 1981-04-10 1984-05-08 Parker-Hannifin Corporation Medication infusion pump
US4439196A (en) 1982-03-18 1984-03-27 Merck & Co., Inc. Osmotic drug delivery system
US4447224A (en) 1982-09-20 1984-05-08 Infusaid Corporation Variable flow implantable infusion apparatus
US4487603A (en) 1982-11-26 1984-12-11 Cordis Corporation Implantable microinfusion pump system
US4486194A (en) 1983-06-08 1984-12-04 James Ferrara Therapeutic device for administering medicaments through the skin
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
JP2020521742A (ja) * 2017-05-25 2020-07-27 アラクセス ファーマ エルエルシー Ｋｒａｓの共有結合性阻害剤
CN114222743A (zh) * 2019-08-16 2022-03-22 劲方医药科技(上海)有限公司 氧代六元环并嘧啶类化合物，其制法与医药上的用途

Also Published As

Publication number Publication date
JP2024510606A (ja) 2024-03-08
AU2022232523A1 (en) 2023-11-16
EP4305038A1 (en) 2024-01-17
CA3210053A1 (en) 2022-09-15
US20240317769A1 (en) 2024-09-26
BR112023017763A2 (pt) 2023-10-03
KR20230169967A (ko) 2023-12-18
WO2022192794A1 (en) 2022-09-15
IL305568A (en) 2023-10-01

Similar Documents

Publication Publication Date Title
MX2023010430A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten con mutacion g12d (kras g12d).
MX2023010429A (es) Inhibidores del homologo del oncogen viral del sarcoma de rata kirsten (kras).
MX2021014177A (es) Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
MX2020012261A (es) Inhibidores de kras g12c que comprenden un anillo de piperazina y uso de estos en el tratamiento del cancer.
MX2020012731A (es) Inhibidores de kras g12c y metodos para su uso.
ZA202202559B (en) Kras g12c inhibitors and methods of using the same
MX2021005700A (es) Inhibidores de kras g12c y metodos de uso de los mismos.
MX2020010836A (es) Inhibidores de kras g12c y métodos para su uso.
MX2020011582A (es) Inhibidores de kras g12c y metodos para su uso.
MX2020002502A (es) Inhibidores de kras g12c y metodos para utilizarlos.
MX2023011856A (es) Tratamientos conjuntos que usan inhibidores de la proteína arginina n-metil transferasa 5 (prmt5) para el tratamiento de cáncer.
MX2019011431A (es) Inhibidores de proteina 1 de muerte celular programada (pd-1)/ligando 1 de muerte programada (pd-l1).
MX2022005726A (es) Sintesis mejorada del compuesto inhibidor de g12c de kras.
MX2022000050A (es) Compuestos heterocíclicos como inhibidores de bromodominio extraterminal (bet).
MX2021016049A (es) Metodos de uso de inhibidores de rad51 para el tratamiento de cancer de pancreas.
MX2022001019A (es) Amidas heterobiciclicas como inhibidoras del cumulo de diferenciacion 38 (cd38).
MX2024005228A (es) Inhibidores de la sustitución de glicina a cisteína en la posición 12 (g12c) en el homólogo del oncogén viral de sarcoma de rata kirsten (kras).
WO2019023315A3 (en) RAC INHIBITORS
MX2023004518A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2021011524A (es) Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos.
UA85087C2 (en) Monocyclic heterocycles as kinase inhibitors
MX2024002391A (es) Inhibidores de indolina de kif18a.
MX2022000310A (es) Inhibidores de proteina bcl-2.
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.